Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
27 Results for "
Phosphodiesterase 10A
" in MedChemExpress (MCE) Product Catalog:
Products (27)
27 Results for "Phosphodiesterase 10A" in MCE Product Catalog:
1
1 Cited Publications
Target:
Research Areas:
1
1 Cited Publications
Target:
Research Areas:
THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species .
Target:
Research Areas:
N-Methylbenzamide is a potent phosphodiesterase 10A (PDE10A) inhibitor. N-Methylbenzamide has anti-cancer activity .
Cat. No.: HY-18078
CAS No.: 927691-21-2
Target:
Research Areas:
PQ-10 is a potent inhibitor of Phosphodiesterase 10A (PDE10A) with IC50 andED50 of 4.6 nM and 13 mg/kg, respectively. PQ-10 induces patterns of brain glucose metabolism which can be a potential translational biomarker. PQ-10 has the potential for researching psychiatric disorders like schizophrenia .
Target:
Research Areas:
AMG 579 is a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A) with an IC50 of 0.1 nM.
Cat. No.: HY-152838
CAS No.: 1380329-87-2
Synonyms: RO554965
Target:
Research Areas:
Gemlapodect (RO554965) is an inhibitor of phosphodiesterase 10A (PDE10A). Gemlapodect can be used for researching schizophrenia .
Cat. No.: HY-148954
CAS No.: 1620909-95-6
Research Areas:
PBF-999 is a phosphodiesterase10A (PDE-10A) and adenosine A2A receptor (A2AR) dual antagonist.
Cat. No.: HY-153168
CAS No.: 112018-01-6
Target:
Research Areas:
Bemoradan (compound 10a) is an orally active and selective canine Phosphodiesterase (PDE) fraction III inhibitor. Bemoradan is a long-acting, potent, inotropic vasodilator and a novel cardiotonic agent, and can be used in congestive heart
failure research .
Target:
Research Areas:
PDE10-IN-1 is a highly potent and selective phosphodiesterase 10A (PDE10A) inhibitor. PDE10-IN-1 regulates neuronal signaling by inhibiting PDE10A-mediated hydrolysis of cAMP/cGMP in the striatum. PDE10-IN-1 can be used in the research of central nervous system diseases, metabolic diseases, neurological disorders, psychosis, schizophrenia, obesity and diabetes .
Cat. No.: HY-123743
CAS No.: 1334165-90-0
Target:
Research Areas:
JNJ-42314415 is a centrally active phosphodiesterase 10A (PDE10A) inhibitor, with Ki values of 35 nM and 64 nM for human recombinant PDE10A and rPDE10A, respectively .
Cat. No.: HY-178987
CAS No.: 3067849-10-6
Research Areas:
BJH-86 is a soluble mitochondrial complex 1 inhibitor (oxygen consumption rate inhibition IC50 = 5 μM). BJH-86 exhibits weak inhibitory activity against phosphodiesterase 10A (PDE10A) (IC50 >10 μM). BJH-86 can reduce cellular oxygen consumption and inhibit cancer cell proliferation. BJH-86 can be used for the research of cancer, such as lung cancer .
Cat. No.: HY-160111
CAS No.: 1404488-48-7
Target:
Research Areas:
PDM-042 is a potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor. PDM-042 shows potent inhibitory activities for human and rat PDE10A with IC50 values of less than 1 nM and more than 1000-fold selectivity against other phosphodiesterases. PDM-042 can be used for the research of schizophrenia .
Cat. No.: HY-128349
CAS No.: 1332727-40-8
Target:
Research Areas:
MT-3014 is a potent, highly selective and brain-penetrated phosphodiesterase 10A (PDE 10A) inhibitor, with IC50s of 0.062 nM and 0.09 nM for human PDE 10A and bovine PDE 10A, respectively .
Cat. No.: HY-117838
CAS No.: 1257051-56-1
Target:
Research Areas:
Phosphodiesterase 10-IN-2 (THPP-4) is an oral active phosphodiesterase 10A (PDE10A) inhibitor with the Ki of 4.5 nM. Phosphodiesterase 10-IN-2 can be used for study of schizophrenia .
Cat. No.: HY-158237
CAS No.: 1006889-85-5
Target:
Research Areas:
PDE10A-IN-3 (Compound 8a) is an inhibitor of phosphodiesterase 10A (PDE10A). PDE10A-IN-3 can be used in schizophrenia research .
Cat. No.: HY-18037
CAS No.: 947192-73-6
Target:
Research Areas:
AMG-7980 exhibits high affinity to phosphodiesterase 10A (PDE10A), with a KD of 0.94 nM. AMG-7980 can be used as a tracer of PDE10A, when labeled with radioactive isotope .
Cat. No.: HY-161663
CAS No.: 3047610-96-5
Target:
Research Areas:
Phosphodiesterase-IN-2 (Compound C7) is a selective, orally active inhibitor for phosphodiesterase 10A (PDE10A), with an IC50 of 11.9 nM. Phosphodiesterase-IN-2 improves the stability of liver microsomes, and lowers BBB permeability. Phosphodiesterase-IN-2 exhibits good pharmacokinetic characters, and attenuates isoprenaline (HY-108353)-induced cardiac hypertrophic in mouse models .
Cat. No.: HY-120022
CAS No.: 1393750-01-0
Target:
Research Areas:
THPP-2 is a tetrahydropyridopyrimidine-type phosphodiesterase 10A (PDE10A) inhibitor with a Ki of 94 nM. THPP-2 is applicable to the research of schizophrenia .
Cat. No.: HY-P2424
CAS No.: 144396-38-3
Synonyms: CCK-J
Target:
Research Areas:
Cat. No.: HY-10030
CAS No.: 1037309-45-7
Synonyms: PF-2545920 succinate
Target:
Research Areas:
Mardepodect succinate (PF-2545920 succinate) is a potent and specific phosphodiesterase 10A (PDE10A) inhibitor with potential activity in the treatment of schizophrenia. Mardepodect succinate has been further optimized to improve brain penetration and compound-like properties for use in schizophrenia research .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
